Filippo Montemurro

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9207220/filippo-montemurro-publications-by-year.pdf
Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

146 papers	3,767 citations	34 h-index	56 g-index
154 ext. papers	4,575 ext. citations	6.3 avg, IF	5.03 L-index

#	Paper	IF	Citations
146	Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial.. *Tumori*, **2022**, 3008916211067568	1.7	
145	T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer. *Cancers*, **2022**, 14, 2468	6.6	0
144	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). *Clinical Cancer Research*, **2021**, 27, 3443-3455	12.9	2
143	Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition. *Nature Communications*, **2021**, 12, 2498	17.4	4
142	The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer. *Drug Design, Development and Therapy*, **2021**, 15, 2711-2720	4.4	1
141	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. *Npj Breast Cancer*, **2021**, 7, 82	7.8	0
140	Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study. *ESMO Open*, **2020**, 5, e000876	6	4
139	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. *Lancet Oncology, The*, **2020**, 21, 519-530	21.7	159
138	Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. *European Journal of Cancer*, **2020**, 136, 43-51	7.5	3
137	Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial. *JAMA Oncology*, **2020**, 6, 1203-1209	13.4	4
136	Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study. *Cancers*, **2020**, 12,	6.6	2
135	Neoadjuvant or adjuvant chemotherapy in early breast cancer?. *Expert Opinion on Pharmacotherapy*, **2020**, 21, 1071-1082	4	18
134	Cancer of Unknown Primary (CUP): genetic evidence for a novel nosological entity? A case report. *EMBO Molecular Medicine*, **2020**, 12, e11756	12	8
133	Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study. *Oncotarget*, **2020**, 11, 2172-2181	3.3	1
132	Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. *International Journal of Cancer*, **2020**, 147, 160-169	7.5	6
131	Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials?. *Lancet Oncology, The*, **2020**, 21, 21-24	21.7	5
130	Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study. *ESMO Open*, **2020**, 5,	6	1

129	Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. *Annals of Oncology*, **2020**, 31, 1350-1358	10.3	65
128	MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer. *ESMO Open*, **2020**, 5, e000937	6	4
127	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. *Breast Care*, **2020**, 15, 30-37	2.4	
126	Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1. *European Journal of Cancer*, **2019**, 109, 92-102	7.5	41
125	A new player in the treatment of HER2-positive tumours. *Lancet Oncology, The*, **2019**, 20, 748-750	21.7	2
124	Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity. *Breast Journal*, **2019**, 25, 444-449	1.2	2
123	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). *Annals of Oncology*, **2019**, 30, 766-773	10.3	46
122	"Metastatic Cancer of Unknown Primary" or "Primary Metastatic Cancer"?. *Frontiers in Oncology*, **2019**, 9, 1546	5.3	16
121	Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM). *Cancers*, **2019**, 11,	6.6	11
120	Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. *Cancers*, **2019**, 11,	6.6	26
119	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. *Lancet Oncology, The*, **2018**, 19, 474-485	21.7	39
118	Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. *Breast*, **2018**, 40, 45-52	3.6	4
117	Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series. *Breast*, **2018**, 38, 160-164	3.6	6
116	T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer. *Breast*, **2018**, 41, 137-143	3.6	26
115	Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study. *Cancer Medicine*, **2018**, 7, 4339-4344	4.8	15
114	Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer. *Breast*, **2018**, 37, 142-147	3.6	20
113	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). *Science Signaling*, **2018**, 11,	8.8	32
112	Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study. *European Journal of Cancer*, **2018**, 105, 61-70	7.5	6

111	The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment. *American Journal of Surgical Pathology*, **2018**, 42, 1190-1200	6.7	10
110	Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting. *Oncologist*, **2017**, 22, 648-654	5.7	8
109	Trastuzumab emtansine in HER2-positive metastatic breast cancer. *Lancet Oncology, The*, **2017**, 18, 696-697	21.7	5
108	Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study. *Clinical Breast Cancer*, **2017**, 17, 601-610.e2	3	23
107	Primary tumor location predicts the site of local relapse after nipple-areola complex (NAC) sparing mastectomy. *Breast Cancer Research and Treatment*, **2017**, 165, 85-95	4.4	11
106	Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. *European Journal of Cancer*, **2017**, 71, 34-42	7.5	31
105	Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2 Scaffolding Function. *Cancer Cell*, **2017**, 32, 444-459.e7	24.3	44
104	A computer-aided diagnosis (CAD) scheme for pretreatment prediction of pathological response to neoadjuvant therapy using dynamic contrast-enhanced MRI texture features. *British Journal of Radiology*, **2017**, 90, 20170269	3.4	17
103	Treating breast cancer with cell-based approaches: an overview. *Expert Opinion on Biological Therapy*, **2017**, 17, 1255-1264	5.4	4
102	Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases. *ESMO Open*, **2017**, 2, e000253	6	40
101	Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?. *Future Oncology*, **2017**, 13, 2791-2797	3.6	19
100	Efficacy and safety of T-DM1 in the "common-practice" of HER2+ advanced breast cancer setting: a multicenter study. *Oncotarget*, **2017**, 8, 64481-64489	3.3	15
99	New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer. *Expert Opinion on Pharmacotherapy*, **2016**, 17, 2179-2189	4	9
98	Omission of axillary dissection after a positive sentinel lymph-node: Implications in the multidisciplinary treatment of operable breast cancer. *Cancer Treatment Reviews*, **2016**, 48, 1-7	14.4	7
97	Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life. *SpringerPlus*, **2016**, 5, 59		31
96	Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study. *Journal of Cancer Research and Clinical Oncology*, **2016**, 142, 669-78	4.9	12
95	Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence. *Expert Review of Anticancer Therapy*, **2016**, 16, 211-8	3.5	11
94	AKT signaling in ERBB2-amplified breast cancer. *Pharmacology & Therapeutics*, **2016**, 158, 63-70	13.9	37

93	Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer. *Expert Opinion on Investigational Drugs*, **2016**, 25, 393-403	5.9	3
92	Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer. *JAMA Oncology*, **2016**, 2, 445-52	13.4	40
91	p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy. *Oncotarget*, **2016**, 7, 4442-53	3.3	8
90	"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome. *Oncotarget*, **2016**, 7, 17932-44	3.3	26
89	Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study. *PLoS ONE*, **2016**, 11, e0156221	3.7	2
88	Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial	10.3	55
87	Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM). *ESMO Open*, **2016**, 1, e000109	6	1
86	Changing paradigms in the treatment of hormone-receptor positive advanced breast cancer. *Expert Opinion on Pharmacotherapy*, **2016**, 17, 1039-41	4	
85	Breast cancer in BRCA mutation carriers: medical treatment. *Minerva Ginecologica*, **2016**, 68, 557-65	1.2	2
84	HER2-positive metastatic breast cancer: a changing scenario. *Critical Reviews in Oncology/Hematology*, **2015**, 95, 78-87	7	19
83	Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 ⨯ 2 factorial, randomised phase 3 trial. *Lancet, The*, **2015**, 385, 1863-72	40	131
82	A retrospective analysis of the activity and safety of oral Etoposide in heavily pretreated metastatic breast cancer patients. *Breast Journal*, **2015**, 21, 241-5	1.2	10
81	Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. *British Journal of Cancer*, **2015**, 113, 1541-7	8.7	25
80	Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer. *Cell Reports*, **2015**, 11, 564-76	10.6	41
79	Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study. *Oncologist*, **2015**, 20, 880-9	5.7	24
78	Clinical utility of exemestane in the treatment of breast cancer. *International Journal of Womens Health*, **2015**, 7, 551-63	2.8	9
77	Linifanib: current status and future potential in cancer therapy. *Expert Review of Anticancer Therapy* , **2015**, 15, 677-87	3.5	16
76	Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer. *Expert Opinion on Investigational Drugs*, **2015**, 24, 421-31	5.9	23

75	By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy. *Oncotarget*, **2015**, 6, 2315-30	3.3	36
74	Biomarkers of drugs targeting HER-family signalling in cancer. *Journal of Pathology*, **2014**, 232, 219-29	9.4	47
73	Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. *Molecular Oncology*, **2014**, 8, 20-6	7.9	34
72	Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. *Breast*, **2014**, 23, 44-9	3.6	20
71	Pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy. *Breast*, **2014**, 23, 690-1	3.6	2
70	Metastatic breast cancer subtypes and central nervous system metastases. *Breast*, **2014**, 23, 623-8	3.6	64
69	Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. *Breast Cancer Research and Treatment*, **2014**, 148, 511-23	4.4	23
68	2013 San Antonio Breast Cancer Symposium. *Expert Opinion on Pharmacotherapy*, **2014**, 15, 1191-5	4	
67	HER2 expression and efficacy of T-DM1. *Breast Cancer Research*, **2014**, 16, 478	8.3	1
66	Vertebral augmentation with nitinol endoprosthesis: clinical experience in 40 patients with 1-year follow-up. *CardioVascular and Interventional Radiology*, **2014**, 37, 193-202	2.7	8
65	Duration of trastuzumab for HER2-positive breast cancer. *Lancet Oncology, The*, **2013**, 14, 678-9	21.7	3
64	Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines. *Journal of Pathology*, **2013**, 229, 390-9	9.4	16
63	Upfront adjuvant aromatase inhibitors in women with lobular breast cancer. *European Journal of Cancer*, **2013**, 49, 3376-7	7.5	1
62	Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. *Annals of Oncology*, **2013**, 24, 1740-1748	10.3	63
61	Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. *Annals of Oncology*, **2013**, 24, 2715-24	10.3	84
60	Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. *Cancer*, **2012**, 118, 17-26	6.4	49
59	Percutaneous vertebroplasty in multiple myeloma: prospective long-term follow-up in 106 consecutive patients. *CardioVascular and Interventional Radiology*, **2012**, 35, 139-45	2.7	34
58	Omission of axillary dissection after a positive sentinel node dissection may influence adjuvant chemotherapy indications in operable breast cancer patients. *Annals of Surgical Oncology*, **2012**, 19, 3755-61	3.1	15

57	Clinical and radiological predictors of nipple-areola complex involvement in breast cancer patients. *European Journal of Cancer*, **2012**, 48, 2311-8	7.5	47
56	A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy. *Oncology Letters*, **2012**, 3, 819-824	2.6	11
55	Potential of afatinib in the treatment of patients with HER2-positive breast cancer. *Breast Cancer: Targets and Therapy*, **2012**, 4, 131-7	3.9	11
54	Correlations between diffusion-weighted imaging and breast cancer biomarkers. *European Radiology*, **2012**, 22, 1519-28	8	164
53	Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. *Annals of Oncology*, **2012**, 23, 1436-41	10.3	25
52	Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer. *Oncologist*, **2012**, 17, 1418-25	5.7	35
51	Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. *Expert Opinion on Pharmacotherapy*, **2012**, 13, 2143-56	4	6
50	Imaging as a potential tool for subtyping breast cancer. *Imaging in Medicine*, **2012**, 4, 577-579	1	
49	Neoadjuvant Therapy in Breast Cancer **2012**, 95-108		
48	Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. *Oncology Reports*, **2011**, 25, 1545-8	3.5	4
47	Trastuzumab in the adjuvant setting: a practical review. *Therapy: Open Access in Clinical Medicine*, **2011**, 8, 161-177		
46	HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. *Breast Cancer Research and Treatment*, **2011**, 130, 29-40	4.4	37
45	Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. *BMC Cancer*, **2011**, 11, 31	4.8	68
44	Percutaneous vertebroplasty in osteoporotic patients: an institutional experience of 1,634 patients with long-term follow-up. *Journal of Vascular and Interventional Radiology*, **2011**, 22, 1714-20	2.4	23
43	Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?. *Expert Opinion on Pharmacotherapy*, **2011**, 12, 549-65	4	7
42	Variation of breast vascular maps on dynamic contrast-enhanced MRI after primary chemotherapy of locally advanced breast cancer. *American Journal of Roentgenology*, **2011**, 196, 1214-8	5.4	13
41	Trastuzumab beyond progression in retrospective analyses: an issue of equal opportunities. *Oncologist*, **2011**, 16, 534-6	5.7	1
40	Role of trastuzumab in the management of HER2-positive metastatic breast cancer. *Breast Cancer: Targets and Therapy*, **2010**, 2, 93-109	3.9	6

39	Underuse of anthracyclines in women with HER-2+ advanced breast cancer. *Oncologist*, **2010**, 15, 665-72	5.7	8
38	Anthracycline-based adjuvant chemotherapy in breast cancer. *Lancet, The*, **2010**, 375, 1871; author reply 1871-2	40	
37	Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison. *BMC Cancer*, **2010**, 10, 28	4.8	13
36	Trastuzumab beyond disease progression: case closed?. *Journal of Clinical Oncology*, **2009**, 27, e121-2; author reply e124-5	2.2	5
35	Reply to A. Sánchez-Muñoz et al. *Journal of Clinical Oncology*, **2009**, 27, e257-e258	2.2	
34	Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy. *Endocrine-Related Cancer*, **2009**, 16, 1091-102	5.7	23
33	Aromatase inhibitors as adjuvant therapy for breast cancer. *Journal of Clinical Oncology*, **2009**, 27, 2566-7	2.2	7
32	Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. *BMC Cancer*, **2008**, 8, 209	4.8	8
31	Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. *Clinical Breast Cancer*, **2008**, 8, 436-42	3	21
30	Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial. *Journal of Clinical Oncology*, **2008**, 26, 2052-3; author reply 2053-4	2.2	10
29	Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. *Annals of Oncology*, **2007**, 18, 977-84	10.3	406
28	Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer. *European Radiology*, **2007**, 17, 1490-7	8	45
27	Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis. *Acta Oncologica*, **2007**, 46, 664-8	3.2	42
26	Does addition of lapatinib to capecitabine improve outcome in women with refractory breast cancer?. *Nature Clinical Practice Oncology*, **2007**, 4, 398-9		2
25	Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. *Expert Opinion on Biological Therapy*, **2007**, 7, 257-68	5.4	84
24	Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. *Annals of Oncology*, **2007**, 18, 1963-8	10.3	9
23	Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference San Antonio, TX, USA, 14-17 December 2007. *Expert Opinion on Pharmacotherapy*, **2007**, 8, 1179-88	4	
22	Trastuzumab treatment in breast cancer. *New England Journal of Medicine*, **2006**, 354, 2186; author reply 2186	59.2	9

21	Jaw complications in breast and prostate cancer patients treated with zoledronic acid. *Acta Oncologica*, **2006**, 45, 216-7	3.2	18
20	Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer. *Annals of Oncology*, **2006**, 17, 1631-6	10.3	25
19	Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. *Oncologist*, **2006**, 11, 318-24	5.7	105
18	A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. *British Journal of Cancer*, **2005**, 92, 1261-7	8.7	23
17	Controversies in breast cancer: adjuvant and neoadjuvant therapy. *Expert Opinion on Pharmacotherapy*, **2005**, 6, 1055-72	4	5
16	Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer. *Clinical Breast Cancer*, **2005**, 6, 77-80	3	17
15	Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer. *European Radiology*, **2005**, 15, 1224-33	8	33
14	TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. *Oncogene*, **2005**, 24, 3002-10	9.2	101
13	The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. *Cancer*, **2005**, 103, 1314-5; author reply 1315	6.4	4
12	Continuation of trastuzumab beyond disease progression. *Journal of Clinical Oncology*, **2005**, 23, 2866-8; discussion 2868-9	2.2	18
11	HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment. *Oncology Reports*, **2005**, 13, 305-9	3.5	17
10	A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. *Oncology*, **2004**, 66, 38-45	3.6	45
9	Trastuzumab-based combination therapy for breast cancer. *Expert Opinion on Pharmacotherapy*, **2004**, 5, 81-96	4	39
8	Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. *Breast Cancer Research and Treatment*, **2004**, 83, 67-76	4.4	207
7	HER2 and central nervous system metastasis in patients with breast cancer. *Clinical Breast Cancer*, **2004**, 5, 232-4	3	7
6	Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2003**, 26, 95-7	2.7	25
5	Dose-dense vinorelbine and paclitaxel with granulocyte colony-stimulating factor in metastatic breast cancer patients: anti-tumor activity and peripheral blood progenitor cell mobilization capability. *Breast Cancer Research and Treatment*, **2003**, 82, 185-90	4.4	8
4	Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. *Biology of Blood and Marrow Transplantation*, **2003**, 9, 330-40	4.7	6

3	Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy. *Radiologia Medica*, **2003**, 106, 51-8	6.5	12
2	High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends. *Clinical Breast Cancer*, **2000**, 1, 197-209; discussion 210	3	6
1	Immunophenotypic heterogeneity of hyalinizing trabecular tumours of the thyroid. *Histopathology*, **1997**, 31, 525-33	7.3	42